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ABSTRACT 
Background: Hypercalciuria is the most frequent metabolic disorder encountered in kidney 
stone formers. Reduced renal phosphate reabsorption (i.e. renal phosphate leak) was proposed 
to be a driver of hypercalciuria in calcium stone formers. However, the phenotype of stone 
formers with renal phosphate leak remains poorly defined, and the association of renal 
phosphate leak with stone history, stone composition and bone mineral density has not been 
studied.  
Methods: To fill these knowledge gaps, we conducted a cross-sectional analysis in a cohort 
of 555 idiopathic calcareous stone formers. The ratio of tubular maximum reabsorption of 
phosphate to glomerular filt ation rate (TmP/GFR) was used to evaluate renal phosphate 
transport. 
Results: Multivariable regression analyses revealed a negative association of PTH, a positive 
association of 25(OH) and 1,25(OH)2 vitamin D but no association of FGF23 with TmP/GFR. 
Stone formers with low TmP/GFR had their first stone event at a younger age and were more 
likely to have a positive family history of kidney stones. In addition, urinary calcium 
excretion and prevalence of brushite stones were significantly higher in stone formers with 
low TmP/GFR. However, bone mineral density, measured by dual-energy x-ray 
absorptiometry, was not associated with TmP/GFR in stone formers.  
Conclusions: Renal phosphate handling has a strong heritable component in stone formers 
and correlates with PTH, 25-VitD and 1,25-VitD, but not with FGF23 levels. Furthermore, a 
low TmP/GFR (i.e. a renal phosphate leak) is associated with higher urinary calcium 
excretion and an increased prevalence of brushite stones. 
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INTRODUCTION 
Nephrolithiasis is a worldwide healthcare problem with a current lifetime risk of ~18.8 % in 
men and ~9.4 % in women in Western civilizations [1]. 80-90 % of stones are composed of 
calcium oxalate, calcium phosphate or a mixture of both. Hypercalciuria is the most frequent 
metabolic abnormality encountered in idiopathic calcium stone formers (SF) [2]. 
Supersaturation of urinary calcium oxalate and calcium phosphate are two of the major 
driving forces for calcium stone formation. Although many inherited and acquired systemic 
diseases underlie calcium stone formation, most stones are designated broadly as idiopathic 
by exclusion [3]. The prevalence of a renal phosphate leak, i.e. hypophosphatemia in 
conjunction with inappropriately low renal tubular phosphate reabsorption, has been reported 
to be as high as 53 % in recurrent SF but also present but much less prevalent in healthy 
individuals [4-8]. Hypophosphatemia-stimulated 1,25(OH)2 with secondary augmentation of 
intestinal calcium absorption has been postulated to cause hypercalciuria (absorptive 
hypercalciuria type III ) in a subgroup of calcium SF [7, 9-11]. However, the evidence 
supporting such a mechanism has been inconclusive. With the exception of one study [4], no 
differences in urinary calcium excretion or 1,25(OH)2 vitamin D levels were detected between 
SF with and without renal phosphate leak [7, 8, 12]. Compared to healthy non-stone forming 
controls, 1,25(OH)2 vitamin D levels have been reported as increased [4] or unchanged [12, 
13] in SF with renal phosphate leak.  
The mechanisms responsible for renal phosphate leak in idiopathic SF remain unclear. A 
previous study suggested that the renal phosphate leak was closely linked to the renal stone 
burden at the time of metabolic work up [6]. In contrast, more recent data suggest that the 
primary abnormality encountered in SF with renal phosphate leak is either a frankly elevated 
or inappropriately normal level of fibroblast growth factor 23 (FGF23) [12]. The latter was 
proposed to be partially caused by an allelic variant of the FGF23 gene (c.C716T; p.T239M) 
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that results in higher FGF23 secretion and increased activation of the FGF receptor/ERK 
signaling pathway [13]. 
Thus, the phenotype of SF with renal phosphate leak remains poorly defined at the moment 
and the role of potential confounders (age, sex, BMI, renal function, comorbidities) largely 
unexplored. Furthermore, the association of renal phosphate leak with stone composition, 
stone frequency and bone mineral density (BMD) has not been studied rendering significant 
impediment for clinicians to recognize and understand this disorder. To address these issues, 
we conducted a cross-sectional analysis in our cohort of idiopathic calcium SF.  
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MATERIALS AND METHODS 
 
Study population and protocol 
The study was conducted with patients recruited at the Division of Nephrology and 
Hypertension at the Bern University Hospital, Bern, Switzerland with approval of the Ethical 
Committee of the Kanton Bern. All participants provided written informed consent and the 
study was conducted in accordance with the Declaration of Helsinki. Patients were seen at the 
Division between March 2004 and June 2016. Inclusion criteria for this study were: informed 
consent, age ≥ 18 years and at least one calcium stone episode. Calcium stone was defined as 
i) at least one stone analysis with a calcium containing stone or ii) radiopaque stone by plain 
abdominal X-ray or iii) > 500 Hounsfield unit stone on computed tomography. Patients were 
excluded from the study analysis based on the following criteria: primary 
hyperparathyroidism or history of parathyroidectomy; sarcoidosis; primary or enteric 
hyperoxaluria; chronic pancreatitis; chronic diarrhea; complete distal renal tubular acidosis 
(dRTA); known cystinuria or elevated 24 h cystine excretion; uric acid nephrolithiasis; 
chronic liver disease or more than threefold elevated liver enzymes;  BMI < 16 or > 40 kg/m
2
; 
history of anorexia nervosa or bulimia, active malignant diseases; pregnancy during the study 
visit; history of solid organ transplantation; hypocortisolism; hyperthyroidism with a TSH < 
0.1 mU/l; total plasma calcium >2.5 mmol/l with a PTH >65 pg/ml; administration of the 
following drugs: over-the-counter or prescribed calcium and/or vitamin D supplements, 
phosphate, bisphosphonates, cinacalcet, denusomab, teriparatide, systemic glucocorticoids or 
mineralocorticoids, antiepileptics, carboanhydrase inhibitors, diuretics. All variables 
employed for study analyses were verified by manual review of the original patient charts by 
NAD, DL, LS, CM and DGF. In the final analysis, 555 SF were included. 
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Data collection and measurements 
Patients collected two 24 h urines on a random outpatient diet and a spot urine and a fasting 
blood draw were performed in the morning after the second 24 h urine collection. All blood 
parameters were determined from the same blood draw. Plasma FGF23 was measured at the 
laboratory of TECOmedical AG (Sissach, Switzerland) by the second generation C-terminal 
assay (Immutopics, San Clemente, CA) with plasma samples frozen at the time of sampling 
and stored at – 80° C. All other urine and blood analyses were performed at the Central 
Laboratory of the Bern University Hospital as single measurements immediately after 
sampling. Assay characteristics for the measurements of FGF23, PTH, 25-OH Vitamin D, and 
1,25(OH)2 vitamin D, were recently described [14]. The glomerular filtration rate GFR was 
estimated by the creatinine-based CKD-EPI 2009 equation [15]. Urinary creatinine excretion 
was used as the criterion for completeness of 24 h urine collections in individuals with normal 
renal function [16, 17]. Percentiles 2.5 and 97.5 of the 24 h creatinine excretion were 
calculated for each 24-hours urine collection using a linear regression model recently 
published [18]. Completeness of 24 h urine collections was assumed for each subject if the 
total 24 h creatinine excretion was within percentiles 2.5 and 97.5. The mean value of both 24 
h urine collections was used for the calculation of 24 h urinary excretions. 
Corrected plasma calcium was calculated by the formula: Cacorr (mmol/L) = plasma calcium 
measured (mmol/L) + 0.025 × (40 – plasma albumin (g/L)) in case of a plasma albumin ≤40 
g/L. Tubular fractional reabsorption of phosphorus (TRP) was calculated by the formula: TRP 
(%) = (100 – FePO4 (%)). Tubular maximum reabsorption of phosphorus per glomerular 
filtration rate (TmP/GFR in mmol/l) was calculated with the algorithm derived by Kenny and 
Glen [19, 20]. If TRP was ≤ 86%, then the formula: TmP/GFR (mmol/l) = TRP × plasma 
phosphate (mmol/l) was used. If TRP was > 86%, then the formula: TmP/GFR (mmol/l) = 
(0.3 × TRP)/(1 – 0.8 × TRP) × (plasma phosphate (mmol/l)) was used. Both TRP and 
TmP/GFR were calculated using 24 h urine samples. Diabetes was defined as reported, 
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treated, fasting glycemia ≥7 mmol/L (≥126.13 mg/dl), or random glycemia ≥11.1 mmol/L 
(≥200 mg/dl). Hypertension was defined as reported, treated, a mean systolic BP ≥140 
mmHg, or a mean diastolic BP ≥90 mmHg. Osteodensitometry was performed at the 
Department of Osteoporosis at the University Hospital of Bern, Switzerland at the time of 
biochemical work-up by dual-energy X-ray absorptiometry (DEXA; Hologic QDR 4500A, 
Hologic, Bedford, MA, USA) at the lumbar spine, the non-dominant femoral neck, the 
proximal femur and the distal tibia diaphysis and epiphysis as described [21, 22]. 
 
Statistical analysis 
All statistical analyses were conducted using the R software, version 3.2.2 [23]. The shape of 
the distribution of each continuous variable was visually inspected and transformations were 
applied where appropriate to ensure normality for statistical analyses. All statistical tests were 
two-sided and a p value <0.05 was considered statistically significant. To estimate 
associations of renal phosphate handling as a continuous phenotype, i.e. TmP/GFR, with 
baseline characteristics, laboratory parameters, kidney stone and bone turnover parameters, 
we applied univariable mixed effects linear and logistic regression analyses. Due to the 
physiological seasonal variation of vitamin D levels, calendar day of blood sampling was 
taken as random effect into account in all mixed effects regression models. Independent 
associations of urinary phosphate leak with variables of interest were analyzed by 
multivariable mixed effects linear and logistic regression containing sex, age, BMI, GFR 
(CKD-EPI), diabetes mellitus (yes or no) and hypertension (yes or no). Multivariable 
regression models were visualized using the R package visreg, which allows to show the 
relationship between TmP/GFR and characteristics of interest while holding the effect of all 
other co-variables in the model constant [24]. For visualization, regression models were re-
created without including a random effect.   
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RESULTS 
Characteristics of study population 
We included adult SF with idiopathic calcium stones in the study. A total of 555 SF met the 
inclusion criteria (age ≥ 18 years, written informed consent, at least one episode with a 
calcium containing kidney stone) and had no exclusion criterion (for details see Materials and 
Methods).  
Demographic and anthropometric characteristics, stone analyses and bone density 
measurements of study participants are shown in Table 1. The majority of patients were male 
(77 %), median age was 43 years and most patients had recurrent stone disease (82 %).  Dual-
energy X-ray absorptiometry (DEXA)-based bone density measurements were available in 
423 of 555 patients (76.2 %). Blood and urinary parameters of participants are depicted in 
Table 2. The distribution of TmP/GFR in our cohort of calcareous SF is shown in Fig. 1.  
 
Association analyses 
Renal phosphate handling in SF was assessed by the ratio of tubular maximum reabsorption 
of phosphate to glomerular filtration rate (TmP/GFR). We first performed association 
analyses by mixed effects linear regression with TmP/GFR as outcome variable and baseline 
characteristics, blood and urine parameters as predictor variables (Table 3). In both 
univariable and multivariable analyses, calendar day of blood sampling was taken as random 
effect into account. Multivariable analyses were adjusted for the covariables age, sex, BMI, 
GFR, diabetes and hypertension. Male sex (β: -0.06, p<0.001) and arterial hypertension (β: -
0.05, p<0.01) were found to be inversely associated with TmP/GFR in multivariable analyses. 
Consistent with previous reports, we found a positive association of TmP/GFR with GFR (β: 
0.0013, p=0.021). There was a strong negative association of PTH (β: -0.002, p<0.001) and a 
strong positive association of 25(OH) vitamin D (β: 0.001, p<0.01) with TmP/GFR. Given the 
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fact that vitamin D status strongly influences PTH secretion, we performed a second 
multivariable analysis where the association of PTH with TmP/GFR was additionally adjusted 
for 25(OH) vitamin D levels. As shown in Table 4, adjusting for 25(OH) vitamin D greatly 
weakened the association of PTH with TMP/GFR to borderline significance (β: -0.001, 
p=0.037). 
In multivariable analyses we also observed a weak positive correlation of 1,25(OH)2 vitamin 
D (β: 0.0004, p<0.05) with TmP/GFR, but no association was found for FGF23 (β: <0.0001, 
p=0.87). Interestingly, there was also an inverse association of 24 h urinary calcium excretion 
(β: -0.006, p<0.05) and a positive association of 24 h urinary oxalate excretion (β: 0.05, 
p<0.01) with TmP/GFR. In contrast, 24 h urinary glycolate excretion, a marker of endogenous 
oxalate metabolism, did not correlate with TmP/GFR (β: -0.04, p=0.13). Figure 2 shows 
visualization of multivariable regression analyses for the associations of PTH, FGF23, 
25(OH)2 vitamin D, 1,25(OH)2 vitamin D and 24 h urinary calcium and oxalate excretion with 
TmP/GFR. 
We next performed association analyses with TmP/GFR as predictor variable and kidney 
stone history, stone analysis and bone parameters as outcome variables (Table 4). After 
multivariable adjustment, renal phosphate leak (i.e. a low TmP/GFR) was associated with a 
higher frequency of positive family history of renal stone disease (OR: 0.3, p<0.05) and with 
a significantly increased likelihood for younger onset of a first stone event (OR: 8.2, p<0.01). 
However, we observed no significant association of TmP/GFR with stone recurrence 
frequency. Interestingly, renal phosphate leak (low TmP/GFR) was associated with an 
increased risk for brushite containing stones (OR 0.006, p<0.01) with a concomitant reduced 
risk for calcium oxalate containing stones (OR 219, p<0.01). BMD measured by dual-energy 
x-ray absorptiometry (DEXA) at the lumbar spine, femoral neck, tibia diaphysis and epiphysis 
as well as the bone turnover marker alkaline phosphatase did not reveal a significant 
association with TmP/GFR. Figure 3 shows again visualization of multivariable regression 
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models for the association of TmP/GFR with family history of stone disease, age of first stone 
event, probability of calcium oxalate, calcium phosphate, apatite or brushite containing 
stones.  
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DISCUSSION 
Classically, SF are dichotomized with respect to renal phosphate handling [4-8, 12, 25]. The 
analysis of our cohort of 555 idiopathic calcium SF demonstrates that TmP/GFR does not 
have a bimodal distribution but is rather a continuous trait, which is compatible with a 
previous study [4]. For our association analyses, we choose to treat renal phosphate handling, 
i.e. TmP/GFR, as a continuous variable. Our results reveal a strong heritable component of 
kidney stone disease in SF with low TmP/GFR, suggesting that genetic factors play an 
important role in renal phosphate handling in SF. Support for this notion comes from 
Mendelian forms of calcareous nephrolithiasis associated with sodium/ phosphate co-
transporter IIa and IIc gene mutations (SLC34A1 and SLC34A3, respectively) and recent 
genome-wide association studies and candidate gene sequencing both reported an association 
of sequence variants in the SLC34A1 gene with kidney stone disease [26-29]. 
We failed to confirm previous reports of an association of FGF23 with TmP/GFR in SF [12, 
13]. The reason for this is not clear and maybe due to different genetic background or diets 
(outpatient versus controlled) of patients studied [4, 12]. Another explanation maybe the fact 
that we measured FGF23 with the second generation C-terminal assay for FGF23, which 
detects both intact FGF23 and C-terminal fragments thereof and thus may overestimate 
“bioactive” FGF23 [30, 31]. Hence, it is possible that we missed an association of “bioactive” 
intact FGF23 with TmP/GFR. However, a recent study using an intact FGF23 assay also 
failed to observe an association of FGF23 with fractional phosphate excretion in SF [32]. 
Instead of FGF23, our multivariable regression analyses indicate that PTH, 25(OH) vitamin D 
and 1,25(OH)2 vitamin D all showed a significant association with renal phosphate handling 
in SF. The cause of increased PTH in SF with phosphate leak cannot be deduced from our 
cross-sectional analysis. The finding that adjustment for the co-variable 25(OH) vitamin D 
greatly attenuates the association of PTH with TmP/GFR suggests that low 25-OH-Vitamin 
Page 45 of 63 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 12 of 26 
 
D3 levels may drive a secondary PTH elevation and thus TmP/GFR reduction in stone 
formers. If this is indeed the case can only be confirmed by a prospective study.  
Our analyses reveal that urinary calcium excretion is increased but 1,25(OH)2 vitamin D 
decreased in SF with low TmP/GFR.  This suggests that not 1,25(OH)2 vitamin D but other, 
as of yet unidentified factors, are involved in the increase of urinary calcium excretion in the 
setting of low TmP/GFR. Interestingly, we also observed lower urinary oxalate excretion in 
SF with renal phosphate leak whereas urinary excretion of the metabolic oxalate precursor 
glycolate was unaltered, indicating that the difference may be caused by reduced 
gastrointestinal oxalate absorption or enhanced gastrointestinal oxalate secretion compared to 
SF with high TmP/GFR. In line with these biochemical urinary alterations in SF with low 
TmP/GFR, our results demonstrate for the first time an increased prevalence of brushite 
stones and a reduced prevalence of calcium oxalate stones in SF with renal phosphate leak.  
Chronic hypophosphatemia causes osteomalacia with elevated alkaline phosphatase and 
reduced BMD [33]. Our results are surprising in that they reveal no reduction of BMD and no 
alteration of alkaline phosphatase in SF with low TmP/GFR. Together with our observation of 
elevated PTH in SF with low TmP/GFR, these results may indicate the presence of a 
resistance to PTH action at the level of the bone. Clearly, measurements of not only total but 
bone-specific alkaline phosphatase activity and of additional bone turnover markers are 
needed to further substantiate this claim. 
To our knowledge, this is by far the largest study to date analyzing the phenotype of SF with 
respect to renal phosphate handling. Our results demonstrate that the clinical phenotype of 
reduced renal phosphate reabsorption in SF has a strong heritable component and correlates 
with higher PTH, 25-VitD and 1,25-VitD, but not with FGF23 levels. Furthermore, our data 
reveal that SF with renal phosphate leak is associated with elevated urinary calcium and an 
increased prevalence of brushite stones.  
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TABLES 
 
Table 1. Baseline characteristics of study population. The number (N) of 
participants is indicated for each characteristic. Categorical variables are described 
by percentage, continuous variables are described by their mean ± SD or median 
(25
th
-75
th
 percentile). 
Characteristics N 
 % or Mean ± SD or 
Median (25
th
-75
th
) 
  Age, y 555 43.4 (34.5-53.9) 
  Male, % 425 76.6 
  Body mass index, kg/m2 555 25.8 (23.2-28.9) 
  Diabetes, % 34 6.1 
  Hypertension, % 267 48.1 
Kidney stone history     
  Positive family history of stones, % 253 46.5 
  Patients with stones available for analysis, % 445 81.1 
  Age at first stone event, y 527 32.7 (24.7-41.6) 
  Patients with stone recurrence, % 452 82.2 
  Number of stone events     
    1 event, % 98 17.8 
    2 events, % 160 29.1 
    3 events, % 116 21.1 
    ≥4 events, % 176 32 
Stone composition (containing)     
  Calcium oxalate, % 418 93.3 
  Calcium phosphate, % 176 39.3 
  Apatite, % 154 34.4 
  Brushite, % 15 3.3 
Bone density parameters     
  T score lumbar spine 422 -0.5 ± 1.1 
  T score femur neck 423 -0.5 ± 1.1 
  T score tibia diaphysis 418 0.4 ± 1.1 
  T score tibia epiphysis 417 -0.6 ± 1 
  Z score lumbar spine 423 0 ± 1.1 
  Z score femur neck 424 0.2 ± 1 
  Z score tibia diaphysis 418 0.6 ± 1.1 
  Z score tibia epiphysis 417 -0.2 ± 0.9 
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Table 2. Blood and urine parameters of study population. The 
number (N) of patients is indicated for each characteristic. 
Continuous variables are indicated by their mean ± SD or by their 
median (25
th
-75
th
 quantile).  
Parameter N 
 Mean ± SD or 
Median (25
th
-75
th
) 
Blood     
  Creatinine, µmol/l 555 78 (68-88) 
  GFR, ml/min per 1.73m
2
 BSA 555 99.1 (86.7-111.1) 
  FGF23, RU/ml 259 66.3 (52.6-90) 
  PTH, pg/ml 553 39 (29.3-47.3) 
  25-OH-Vitamin D3, nmol/l 372 40.7 (27.9-58) 
  1,25-OH-Vitamin D3, pmol/l 540 97 (73-123) 
  Calcium total, mmol/l 555 2.34 ± 0.1 
  Phosphate, mmol/l 555 1.01 ± 0.17 
  Alkaline phosphatase, units/l 553 64 (54-75) 
Urine     
  Sodium, mmol/24 h 527 184 (140-233) 
  Potassium, mmol/24 h 526 62.3 (49.1-78.4) 
  Calcium, mmol/24 h 527 5.94 (4.23-8.38) 
  Phosphate, mmol/24 h 527 30.3 ± 10.1 
  TmP/GFR, mmol/l 555 0.85 ± 0.19 
  pH, 24 h 463 5.97 (5.44-6.62) 
  Citrate, mmol/24 h 517 2.71 (1.74-3.69) 
  NGIA, mmol/24 h 471 34.6 (17.3-49.8) 
  Oxalate, µmol/24 h 517 0.37 (0.26-0.54) 
  Glycolate, µmol/24 h 462 0.36 (0.16-0.54) 
  Sulfate, mmol/24 h 459 22 (17-27.6) 
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Table 3. Association of baseline characteristics and blood and urine parameters with TmP/GFR. Models were calculated by mixed 
effects linear regression taking calendar day of blood sampling as random effect into account. Univariable models contain the predictor 
variables listed with TmP/GFR as outcome variable. Multivariable models were adjusted for the covariables age, sex, BMI, GFR, 
diabetes, and hypertension. For PTH a second multivariable model with additional adjustment for the covariable 25-OH-Vitamin D3 was 
generated.  The number of subjects in each model (N), the β coefficient and its 95% confidence interval (CI), and the p value of the 
predictor variable are indicated. 
    Univariable Models     Multivariable Models 
Predictor variable N β 95% CI p   N β 95% CI p 
Baseline characteristics                   
  Age, y 555 -0.0013 -0.0024;-0.0002 0.024   555 0.0010 -0.0005;0.0026 0.20 
  Sex, Male 555 -0.0737 -0.1087;-0.0387 <0.001   555 -0.0626 -0.0975;-0.0277 <0.001 
  Body mass index, kg/m2 555 -0.0039 -0.0074;-0.0004 0.030   555 -0.0009 -0.0045;0.0028 0.64 
  GFR, ml/min per 1.73m
2
 BSA 555 0.0014 0.0006;0.0022 <0.001   555 0.0013 0.0002;0.0024 0.021 
  Diabetes, % present 555 -0.0232 -0.0859;0.0396 0.47   555 -0.0182 -0.0802;0.044 0.57 
  Hypertension, % present 555 -0.0689 -0.0985;-0.0393 <0.001   555 -0.0540 -0.0868;-0.0211 0.0014 
Blood parameters                   
  FGF23, RU/ml 259 0.0001 -0.0001;0.0002 0.28   259 0.0000 -0.0001;0.0001 0.87 
  PTH, pg/ml 553 -0.0019 -0.0029;-0.001 <0.001   553 -0.0018 -0.0027;-0.0008 <0.001 
  PTH, pg/ml additionally adjusted for  
  25-OH-Vitamin D3, nmol/l 
  D3 
- - - -   372 -0.0013 -0.0026;-0.0001 0.037 
  25-OH-Vitamin D3, nmol/l 372 0.0009 0.0002;0.0016 0.014   372 0.0010 0.0003;0.0018 0.0052 
  1,25-OH-Vitamin D3, pmol/l 540 0.0005 0.0001;0.0009 0.011   540 0.0004 0;0.0008 0.040 
  Calcium total, mmol/l 555 0.1598 0.0034;0.3159 0.045   555 0.2216 0.0684;0.3746 0.0049 
Urine parameters                   
  Sodium, mmol/24 h 527 -0.0001 -0.0003;0.0001 0.48   527 0.0001 -0.0002;0.0003 0.58 
  Potassium, mmol/24 h 526 -0.0004 -0.0011;0.0003 0.27   526 0.0002 -0.0005;0.0008 0.67 
  Calcium, mmol/24 h 527 -0.0075 -0.0126;-0.0025 0.0037   527 -0.0064 -0.0116;-0.0012 0.017 
  Uric acid, µmol/24 h 527 0 0;0 0.0022   527 0 0;0 0.055 
  pH, 24 h 463 -0.0076 -0.0302;0.0146 0.51   463 -0.0162 -0.039;0.0066 0.17 
  Citrate, mmol/24 h 517 -0.0035 -0.0133;0.0064 0.49   517 -0.0020 -0.0119;0.0079 0.69 
  NGIA, mmol/24 h 471 -0.0001 -0.0006;0.0004 0.72   471 -0.0001 -0.0006;0.0004 0.80 
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  Oxalate, µmol/24 h 517 0.0420 0.0017;0.0821 0.040   517 0.0528 0.0134;0.0922 0.0089 
  Glycolate, µmol/24 h 462 -0.0437 -0.0914;0.004 0.073   462 -0.0370 -0.0841;0.0101 0.13 
  Sulfate, mmol/24 h 459 -0.0016 -0.003;-0.0003 0.021   459 -0.0007 -0.0021;0.0007 0.34 
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Table 4. Association of TmP/GFR with kidney stone and bone turnover parameters. Models were calculated by 
mixed effects logistic regression and by mixed effects linear regression taking calendar day of blood sampling as 
random effect into account.  Univariable models for outcome variables listed contain TmP/GFR as predictor variable. 
Multivariable models were adjusted for the covariables  age, sex, BMI, GFR, diabetes and hypertension. The number 
of subjects in each model (N), the odds ratio (OR) or β coefficient and its 95% confidence interval (CI), and the p 
value of the predictor variable are indicated. 
    Univariable Models     Multivariable Models 
Outcome variable N OR/β 95% CI p   N OR/β 95% CI p 
Kidney stone history                   
  Positive family history of stones
a
 544 0.399 0.15;1.07 0.067   544 0.289 0.105;0.798 0.017 
  Age at first stone event, y
a
 527 1.71 -4.25;7.65 0.57   527 8.2 2.77;13.6 0.0033 
  Patients with stone recurrence 550 0.207 0.059;0.725 0.014   550 0.356 0.092;1.37 0.13 
  Number of stone events                   
    1 event 550 4.82 1.38;16.9 0.014   550 2.81 0.72;10.956 0.14 
    2 events 550 0.688 0.247;1.92 0.47   550 0.656 0.227;1.89 0.44 
    3 events 550 0.741 0.237;2.32 0.61   550 0.844 0.252;2.83 0.78 
    ≥4 events 550 0.624 0.227;1.72 0.36   550 0.884 0.294;2.66 0.83 
  Calcium oxalate, present 448 58.2 2.61;1286 0.010   448 219 5.37;8913 0.0044 
  Calcium phosphate, present 448 0.756 0.232;2.47 0.64   448 0.462 0.126;1.7 0.24 
  Apatite, present 448 0.923 0.282;3.02 0.89   448 0.579 0.16;2.1 0.41 
  Brushite, present 448 0.011 0;0.261 0.0051   448 0.006 0;0.157 0.0021 
Bone parameters                   
  T score lumbar spine 422 0.186 -0.41;0.78 0.54   422 0.263 -0.331;0.855 0.39 
  T score femur neck 423 0.355 -0.231;0.941 0.24   423 0.341 -0.222;0.903 0.24 
  T score tibia diaphysis 418 0.005 -0.589;0.603 0.99   418 0.279 -0.315;0.874 0.36 
  T score tibia epiphysis 417 -0.225 -0.762;0.311 0.41   417 -0.040 -0.557;0.474 0.88 
  Z score lumbar spine 423 0.307 -0.318;0.93 0.33   423 0.412 -0.184;1.01 0.18 
  Z score femur neck 424 0.343 -0.224;0.908 0.24   424 0.554 -0.001;1.11 0.052 
  Z score tibia diaphysis 418 0.082 -0.514;0.677 0.79   418 0.352 -0.229;0.941 0.25 
  Z score tibia epiphysis 417 -0.193 -0.715;0.327 0.47   417 -0.011 -0.522;0.499 0.97 
  Alkaline phosphatase, units/l
b
 553 -0.176 -0.653;0.3 0.47   553 0.076 -0.406;0.558 0.76 
a
not adjusted for age, 
b
square root transformed 
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FIGURE LEGENDS 
 
 
Figure 1. Distribution of TmP/GFR in study population. 
Kernel density plot histogram of TmP/GFR in the study cohort of 555 idiopathic calcium SF. 
Left panel: entire cohort. Right panel: cohort separated in men (blue) and women (red). 
 
Figure 2. Visualization of selected multivariable regression models from Table 3. All 
models were calculated by linear regression and are visualized using the R package visreg. 
Solid lines indicate regression lines and the shaped area represents the 95 % confidence 
interval. 
 
Figure 3. Visualization of selected multivariable regression models from Table 4. For 
dichotomous outcome variables, figures were created by an inverse logistic transformation of 
the linear regression line and 95 % confidence bands derived from the logistic regression 
models. The vertical axis for dichotomous outcome variables in logistic regression models is 
labelled with the probability scale and the horizontal axis with the predictor variable of 
interest. 
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